The bill amends the Michigan Consumer Protection Act by adding a new section, 9b, which mandates the attorney general to investigate the pricing of prescription insulin drugs available to residents of Michigan. The investigation aims to ensure adequate consumer protections and assess the need for additional measures. The attorney general is tasked with gathering and analyzing relevant information from manufacturers, pharmacy benefits managers, and other entities involved in the sale of insulin drugs, while also considering publicly available data.

Furthermore, the attorney general is authorized to issue administrative subpoenas to obtain necessary information, although trade secrets are exempt from disclosure. By October 1, 2027, the attorney general must publish a report detailing the findings of the investigation, which will include a summary of insulin pricing practices, public policy recommendations to prevent overpricing, and suggestions for amendments to the act to curb unfair practices in the sale of insulin drugs. The bill is set to take effect 90 days after being enacted into law.

Statutes affected:
House Introduced Bill: 445.901, 445.922